TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00337454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 50mg BID, once daily, 24 weeks.
Study: NCT03541811

Intervention type: DIAGNOSTIC_TEST
Intervention: 3-d gait examination (level walking)
Description: Instrumented 3d-gait-analysis will be carried out in the movement lab of the FH (Fachhochschule; University of Applied Sciences) Campus Wien - University of Applied Sciences. The system used is a 10 camera T40S Vicon system with two floor-mounted AMTI OR6/7-2000 force plates. For assessing gait the Plug-in-Gait Lower Body Model with 14 mm retroreflective skin-mounted markers is implemented in the capturing software Vicon Nexus 2.2. The specific parameters will be extracted from the reporting software Vicon Polygon 4.2.~Markers will be placed by one experienced examiner. Subjects will be instructed to walk barefoot on a 10 meters walkway at self-paced walking speed until five right and five left valid first force plate strikes are captured.

Intervention type: DIAGNOSTIC_TEST
Intervention: 3-d gait examination (level walking)
Description: Instrumented 3d-gait-analysis will be carried out in the movement lab of the FH (Fachhochschule; University of Applied Sciences) Campus Wien - University of Applied Sciences. The system used is a 10 camera T40S Vicon system with two floor-mounted AMTI OR6/7-2000 force plates. For assessing gait the Plug-in-Gait Lower Body Model with 14 mm retroreflective skin-mounted markers is implemented in the capturing software Vicon Nexus 2.2. The specific parameters will be extracted from the reporting software Vicon Polygon 4.2.~Markers will be placed by one experienced examiner. Subjects will be instructed to walk barefoot on a 10 meters walkway at self-paced walking speed until five right and five left valid first force plate strikes are captured.
Study: NCT00337454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70mg BID, once daily, 24 weeks.
Study: NCT03541811

Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometrics and body composition assessment
Description: Body height will be measured with the stadiometer Seca 213 to the next 0.1cm. Body size and weight will be measured without shoes and outerwear. A correction of 1 kg will be subtracted for clothing. Body weight and body composition will be assessed with the medical body composition analyzer Seca mBCA 515 based on bioelectric impedance analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometrics and body composition assessment
Description: Body height will be measured with the stadiometer Seca 213 to the next 0.1cm. Body size and weight will be measured without shoes and outerwear. A correction of 1 kg will be subtracted for clothing. Body weight and body composition will be assessed with the medical body composition analyzer Seca mBCA 515 based on bioelectric impedance analysis.
Study: NCT00629057

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-PRO
Description: 2 x 10e8 TCID50 q 4 wks x 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-PRO
Description: 4 x 10e8 TCID50 q 4 wks x 6
Study: NCT03294122

Intervention type: RADIATION
Intervention: External beam radiotherapy for prostate cancer
Description: Patients will receive radiotherapy for prostate cancer and possible adjuvant hormone therapies as foreseen by international guidelines. No modification of standard regimens is considered. PCa patients are treated with 78 Gy, 2Gy/fraction, in exclusive setting and with 70 Gy, 2Gr/fraction in the post-prostatectomy setting. Lymph node irradiation is performed (50 Gy, 2Gy/fraction) when indicated by risk class.

Intervention type: RADIATION
Intervention: External beam radiotherapy for prostate cancer
Description: Patients will receive radiotherapy for prostate cancer and possible adjuvant hormone therapies as foreseen by international guidelines. No modification of standard regimens is considered. PCa patients are treated with 78 Gy, 2Gy/fraction, in exclusive setting and with 70 Gy, 2Gr/fraction in the post-prostatectomy setting. Lymph node irradiation is performed (50 Gy, 2Gy/fraction) when indicated by risk class.

Intervention type: RADIATION
Intervention: External beam radiotherapy for head and neck cancer
Description: Patients will receive radiotherapy for head and neck cancer and possible concomitant chemotherapies as foreseen by international guidelines. No modification of standard regimens is considered. In curative setting, HNCa patients are treated at a total dose of 70 Gy, 59.4 Gy and 56.1 Gy in 33 fractions to high risk Planning Target Volume (PTV), intermediate risk and low risk PTV, respectively. In high risk post-operative setting they are treated with 66 Gy (according to histopathological features), 60 Gy and 56.1 Gy to high, intermediate and low risk PTV, respectively; while, in intermediate risk post-operative case, intermediate and low risk PTV are irradiated with 60 Gy and 54 Gy, respectively. Chemotherapy will be platinum based (weekly or 3-weekly cisplatin).

Intervention type: RADIATION
Intervention: External beam radiotherapy for head and neck cancer
Description: Patients will receive radiotherapy for head and neck cancer and possible concomitant chemotherapies as foreseen by international guidelines. No modification of standard regimens is considered. In curative setting, HNCa patients are treated at a total dose of 70 Gy, 59.4 Gy and 56.1 Gy in 33 fractions to high risk Planning Target Volume (PTV), intermediate risk and low risk PTV, respectively. In high risk post-operative setting they are treated with 66 Gy (according to histopathological features), 60 Gy and 56.1 Gy to high, intermediate and low risk PTV, respectively; while, in intermediate risk post-operative case, intermediate and low risk PTV are irradiated with 60 Gy and 54 Gy, respectively. Chemotherapy will be platinum based (weekly or 3-weekly cisplatin).
Study: NCT02986256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taking pictures
Description: Photograph of foot ulcer with transmission to referring nurse 1 time per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit at home
Description: Home visit by the referring nurse every 15 days
Study: NCT03064867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Beginning with 400mg daily on days 1-10 of cycle 1-3~Phase I dose escalation scheme:~Dose Level -2 (DL-2): 100 mg daily, days 1-10, cycle 1-3~DL-1: 200 mg daily, days 1-10, cycle 1-3~DL1: 400 mg daily, days 1-10, cycle 1-3~DL2: 600 mg daily, days 1-10, cycle 1-3~DL3: 800 mg daily, days 1-10, cycle 1-3~Phase II: Given at a dose of 400mg daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Part of R-ICE treatment:~Rituximab: 375 mg/m\^2 intravenously (IV) on Day 1 of R-ICE every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Part of R-ICE treatment:~Ifosfamide: 5,000 mg/m\^2 mixed together with mesna at a dose of 5,000 mg/m\^2 over 24 hours beginning on Day 2 and completing on Day 3 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Part of R-ICE treatment:~Carboplatin: At a dose corresponding to an AUC = 5 based on Cockcroft-Gault calculation of GFR using adjusted body weight. Carboplatin is given IV on the Day 2 of RICE of each 21 day cycle
Study: NCT03541811

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers
Description: Blood will be collected into Vacuette serum-separating tubes and will be kept at room temperature for 30 min. Samples will be centrifuged at 1500g for 10 min and serum aliquots will be stored at 80 C until use. Urine samples will be collected into Vacuette tubes containing no additive from non-fasted individuals between 8:00 and 12:00 a.m. Urine samples will be kept at 4 °C for a maximum of 8 h, and then aliquoted and stored at 80 °C.~All biomarkers (except vitamin D and CRP) will be measured in duplicates using standard enzyme-linked immunosorbent assay (ELISA) kits. Serum samples will be assessed for the level of sCOMP, sC1,2C, and sCS846, IL-6, IL-1, sTNFR1 and sTNFR2. Vitamin D and CRP will be measured using automated immunoassay. In urine samples uCTX-II will be determined and these levels will be corrected for creatinine levels (Jaffé method, in-house validated method).

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers
Description: Blood will be collected into Vacuette serum-separating tubes and will be kept at room temperature for 30 min. Samples will be centrifuged at 1500g for 10 min and serum aliquots will be stored at 80 C until use. Urine samples will be collected into Vacuette tubes containing no additive from non-fasted individuals between 8:00 and 12:00 a.m. Urine samples will be kept at 4 °C for a maximum of 8 h, and then aliquoted and stored at 80 °C.~All biomarkers (except vitamin D and CRP) will be measured in duplicates using standard enzyme-linked immunosorbent assay (ELISA) kits. Serum samples will be assessed for the level of sCOMP, sC1,2C, and sCS846, IL-6, IL-1, sTNFR1 and sTNFR2. Vitamin D and CRP will be measured using automated immunoassay. In urine samples uCTX-II will be determined and these levels will be corrected for creatinine levels (Jaffé method, in-house validated method).
Study: NCT03064867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Part of R-ICE treatment:~Etoposide: 100 mg/m2by IV daily on 3 consecutive days (Days 1-3) of each 21-day cycle
Study: NCT01874041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Study: NCT03318757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Extended Release Liposome Injection
Description: Bupivacaine Extended Release Liposome Injection (Exparel TM) 133 mg diluted in 10ml of normal saline (13.3 mg/ml) will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: 10ml of Bupivacaine HCl 0.5% will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
Study: NCT00901524

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Peg-interféron alpha 2a + ribavirin
Description: Pilot study, multicenter, open label
Study: NCT01096641

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: immediate CBT
Description: After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed CBT
Description: After the baseline assessment the fatigued patients will be randomized: this group is to be placed on a waiting list. After 6 months, a second assessment will take place in the group of fatigued patients who received CBT immediately after randomization. This assessment will include the same measurements as at baseline. The fatigued patients on the waiting list will then start with CBT.
Study: NCT03651973

Intervention type: OTHER
Group type: OTHER
Intervention: Standard follow-up
Description: Patients enrolled into standard group will be followed in a standard way without any additional procedure except randomization that allocates to the standard group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning workshops
Description: Patients enrolled into experimental arm will participate to educative workshops before and after surgery for breast cancer. The aim of these workshop is to educate patient to self massages and self stretching.
Study: NCT01916694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue tooth enabled glucose meter with smart phone application
Study: NCT00337454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 90mg BID, once daily, 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70mg BID, once daily, 24 weeks.
Study: NCT01916694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self home blood glucose monitoring
Description: Fingerprick testing of blood glucose levels before and 2 hours after meals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self home blood glucose monitoring
Description: Fingerprick testing of blood glucose levels before and 2 hours after meals
Study: NCT00337454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70mg BID, once daily, 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70mg BID, once daily, 12 weeks.
Study: NCT04195672

Intervention type: DEVICE
Intervention: NIPE (MDoloris®) and CBS values
Description: During different procedures of care with the bed-side nurse, NIPE ware recorded. Monitoring started 15 minutes before care and continuously recorded until 10 minutes after the procedure. Pain assessment was evaluated by the CBS under 3 periods for each patient: 1- before any procedure (T1) representing the baseline, 2- during the procedure of care (T2), and 3- after the procedure (T3). Investigator who performed the CBS was blind to NIPE during the procedure recording.~This study did not change the procedure of care before or after and had no impact on care
Study: NCT02062255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study: NCT02062255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 FFA

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 FFA
Study: NCT03471286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Drug is taken orally two times per day for 14 days, prior to surgical resection of tumor.
Study: NCT03275623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Those randomized for treatment will be prescribed the most commonly used antibiotic for urinary tract infections in pregnancy. This includes: Nitrofurantoin, Cephalexin, and Amoxicillin. It is unsure which antibiotic the participant will receive but a majority of the time it will be one of the above named antibiotic. The choice will be determined by the physician, but will accommodate participants' prior medication history and adverse events.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Prenatal Care
Description: Continued surveillance of urinary cultures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Prenatal Care
Description: Continued surveillance of urinary cultures
Study: NCT03393975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX930
Description: Participants in prophylaxis cohort will receive IV infusions of 40 IU/kg BAX 930 ORT during Period 1 and Period 2 and switch to BAX 930 SIN during Period 3 for six months once in a week or twice in a week. In On-demand cohort participants will receive daily IV dose of BAX-930.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX930
Description: Participants in prophylaxis cohort will receive IV infusions of 40 IU/kg BAX 930 ORT during Period 1 and Period 2 and switch to BAX 930 SIN during Period 3 for six months once in a week or twice in a week. In On-demand cohort participants will receive daily IV dose of BAX-930.
Study: NCT00929006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone suspension
Description: Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
Study: NCT00929006

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Study: NCT01728987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: as in arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsule looking identical to the cholecalciferol capsule
Study: NCT04002869

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunologic, molecular, metabolomic and radiolologic diagnostic
Description: Evaluation and development of new technologies

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunologic, molecular, metabolomic and radiolologic diagnostic
Description: Evaluation and development of new technologies

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunologic, molecular, metabolomic and radiolologic diagnostic
Description: Evaluation and development of new technologies

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunologic, molecular, metabolomic and radiolologic diagnostic
Description: Evaluation and development of new technologies
Study: NCT03393975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will receive Investigator-recommended Standard of care (SoC).
Study: NCT02676310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Study: NCT02602236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AOS-C2000-B
Description: 1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day
Study: NCT04180813

Intervention type: DRUG
Intervention: Linagliptin
Description: drug
Study: NCT03393975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will receive Investigator-recommended Standard of care (SoC).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will receive Investigator-recommended Standard of care (SoC).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will receive Investigator-recommended Standard of care (SoC).
Study: NCT01941342

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatoduodenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENBD and Pancreatoduodenectomy
Study: NCT04002869

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunologic, molecular, metabolomic and radiolologic diagnostic
Description: Evaluation and development of new technologies
Study: NCT04090658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B
Description: Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.
Study: NCT04180813

Intervention type: DRUG
Intervention: Acarbose
Description: drug
Study: NCT02046343

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health education
Description: Group health education sessions delivered by a promotora approximately 90 minutes in length. In the PA arm, health education incorporates at least 30 minutes group exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Group health education sessions delivered by a promotora approximately 90 minutes in length. In the PA arm, health education incorporates at least 30 minutes group exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Brief (10 minute) telephone counseling calls delivered by promotoras using motivational interviewing techniques. The counseling calls will emphasize behavior change strategies, including self-monitoring, goal setting, reinforcement, problem solving, stimulus control, and enlisting social support.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Newsletter
Description: Educational, motivational and informational newsletters tailored for each community and hand-delivered by promotoras to participant homes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Change
Description: Create a site atmosphere that promotes PA and increases the number of PA program offerings.
Study: NCT06322823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct thawing
Description: Vitrified blastocysts will be thawed directly into 1ml G-TL medium

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrification
Description: Vitrified blastocysts will be thawed using commercially available one-step media.
Study: NCT01095250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01984593

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: The participants in the Yoga group will get a private doctors appointment (20 minutes) where they get instructions for two yoga exercises to perform at home 15 minutes twice a day.~The two yoga exercises were:~1. Left nostril breathing - deep breaths in and out through the left nostril while sitting or lying down, with the right nostril closed off by the right thumb or an earplug (about 11 minutes); and~2. Spinal flex - movement that alternates between flexing the spine forwards (arching) and relaxing the spine back in time with deep breaths while sitting in a chair (about 4 minutes).
Study: NCT02058199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: Single dose pharmacodynamic study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: Single dose pharmacodynamic study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: Single dose pharmacodynamic study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: Single dose pharmacodynamic study
Study: NCT02568826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-glycosyl-3-Odemethylthiocolchicine derivative
Description: IDN 5243 is a new muscle relaxant molecule. This molecule has showed significant anti-inflammatory activity by intraperitoneal route at 10 mg/kg in both carrageenan induced oedema and granuloma tests. IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities. The primary packaging of test formulation will be a glass vial containing a solution of IDN 5243, 4 mg/ 1 mL. The secondary package will correspond to the patient's kit and will be a box containing ten (10) vials. The box label will be provided with a tear-off label.
Study: NCT01147315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid bone substitution
Description: The patient will be treated by hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow after necrosis exeresis
Study: NCT02782455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flavonoids
Description: Daflon is administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDobi
Description: Calcium dobesylate is administered